Molecular Insight Pharmaceuticals said that a phase IIB clinical trial of its Zemiva radiopharmaceutical has yielded positive results.
Prospective analysis of the clinical trial data suggests that the addition of quantitative SPECT imaging with Zemiva to clinical information obtained in an emergency department setting has significant clinical value in rapidly identifying chest pain patients at high risk for acute coronary syndrome.
The Cambridge, MA-based firm presented the analysis in a poster at this week's 2008 scientific sessions of the American Heart Association (AHA) in New Orleans.
Related Reading
Molecular Insight installs interim CEO, September 26, 2008
Molecular Insight touts Trofex studies, June 18, 2008
Molecular Insight starts Trofex trial, June 12, 2008
Molecular Insight's revenue decreases in Q1, May 14, 2008
Molecular Insight launches new Azedra trials, May 1, 2008
Copyright © 2008 AuntMinnie.com
